Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Worldwide trends in survival from childhood glioma 2000-2014 (CONCORD-3): preliminary findings and plans for further research.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Fabio Girardi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297

Authors

F. Girardi, V. Di Carlo, A. Bonaventure, C. Allemani, M.P. Coleman, . CONCORD Working Group

Author affiliations

  • Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, WC1E 7HT - London/GB
More

Resources

Background

The CONCORD programme was the first to establish global surveillance of cancer survival. The third cycle (CONCORD-3) collected data from 322 cancer registries in 71 countries. Survival from all brain tumours combined varied widely between countries, particularly in children. We propose to examine survival trends by relevant explanatory variables to help explain these disparities.

Methods

We present the numbers of children diagnosed with a glioma (ICD-O-3 morphology codes 938-948) and by each of the main glioma subtypes. Five-year net survival will be estimated by morphology, WHO grade, topography, sex, country and calendar period of diagnosis. Net survival is the probability that patients survive their cancer until a given time since diagnosis (e.g. 5 years), after controlling for competing risks of death (background mortality).

Results

Data were obtained for 56,507 children (aged 0-14 years) diagnosed with a glioma: 19,080 in Europe, 26,751 in North America, 6,111 in Asia, 3,103 in Central and South America, 1,379 in Oceania and 83 in Africa. In Europe, 5% of gliomas were ependymomas, 26% pilocytic astrocytomas, 8% astrocytomas, not otherwise specified (NOS), 5% glioblastomas NOS and 15% medulloblastomas NOS. The distribution was similar in North America. In Africa, Asia, and Central and South America, and in Oceania, pilocytic astrocytoma was less frequent (10%-13%) than in Europe or North America. In Africa, Asia, and Central and South America, astrocytoma NOS was more common (11-32%). The frequency of medulloblastoma was higher in Central and South America (28%) and Asia (23%). The distribution of the morphologic subtypes of childhood glioma varies widely around the world. Survival differs between morphologic groups. We will assess the extent to which the distribution of morphologic sub-types contributes to international variation in childhood glioma survival worldwide.

Conclusions

When comprehensive survival analyses are available for each type of glioma, this project will become the benchmark for future international comparisons of brain tumour survival in children, to inform cancer control plans.

Clinical trial identification

Legal entity responsible for the study

London School of Hygiene and Tropical Medicine.

Funding

Children With Cancer UK.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings